PAR Share Price Performance
AU$0.34
0.11 (50.00%)
Price AU$0.34
Share PriceAU$0.34
PAR Community Narratives
There are no narratives available yet.
Recent PAR News & Updates
No updates
Paradigm Biopharmaceuticals Limited Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.037
- Gross Margin
- -65.89%
- Net Profit Margin
- -87,171.95%
- Debt/Equity Ratio
- 0%
Paradigm Biopharmaceuticals Limited Competitors
About PAR
- Founded
- 2014
- Employees
- n/a
- CEO
- WebsiteView website
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.
Australian Market Performance
- 7 Days: -0.2%
- 3 Months: 6.6%
- 1 Year: 8.6%
- Year to Date: 5.1%
In the last week, the market has been flat, with a notable exception in the Materials sector dropping 4.2%. Meanwhile, the market is actually up 8.6% over the past year. Looking forward, earnings are forecast to grow by 11% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading